Lannett Inc Revenue Growth Rates (LCINQ), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lannett Company Inc  (NONE: LCINQ)
 

LCINQ's Revenue Growth by Quarter and Year

Lannett Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LCINQ Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter June -
3rd Quarter March 79.46
2nd Quarter December 72.71
1st Quarter September 73.88
FY 226.05

LCINQs Annual Revenue
Lannett Inc's Revenue in the fiscal year 2022 $ 340.58 millions
Lannett Inc's Revenue in the fiscal year 2021 $ 478.78 millions
Lannett Inc's Revenue in the fiscal year 2020 $ 197.24 millions
Lannett Inc's Revenue in the fiscal year 2019 $ 275.81 millions
Lannett Inc's Revenue in the fiscal year 2018 $ 684.56 millions




LCINQ Revenue third quarter 2023 Y/Y Growth Comment
Lannett Company Inc reported Revenue growth of 1.41% year on year in the third quarter 2023, to $ 79.46 millions, this is lower than Lannett Company Inc's recent average Revenue improvement of 23.82%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 147 other companies have achieved higher Revenue growth. While Lannett Company Inc' s Revenue increase of 1.41% ranks overall at the positon no. 2452 in the third quarter 2023.


LCINQ Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter June - -30.02 % 120.35 % -15.97 %
3rd Quarter March 1.41 % -30.27 % 124.78 % -31.73 %
2nd Quarter December -15.95 % -35.4 % 170.82 % -36.58 %
1st Quarter September -27.23 % -19.73 % 154.54 % -26.23 %
FY   - -28.86 % 142.74 % -

Financial Statements
Lannett Inc's third quarter 2023 Revenue $ 79.46 millions LCINQ's Income Statement
Lannett Inc's third quarter 2022 Revenue $ 78.36 millions Quarterly LCINQ's Income Statement


LCINQ Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter June - -5.32 % -5.66 % -3.76 %
3rd Quarter March 9.29 % -9.42 % -16.09 % 1.09 %
2nd Quarter December -1.58 % -14.79 % 5.88 % -0.48 %
1st Quarter September -0.42 % -4.23 % 162.9 % -13.21 %
FY (Year on Year)   - -28.86 % 142.74 % -


Back to LCINQ Growth rate Comparisons >> Back to LCINQ Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #148
Healthcare Sector #402
Overall #2452

Revenue Y/Y Growth Statistics
High Average Low
170.84 % 23.82 % -58.01 %
(Dec 31 2020)   (Mar 31 2019)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #148
Healthcare Sector #402
Overall #2452
Revenue Y/Y Growth Statistics
High Average Low
170.84 % 23.82 % -58.01 %
(Dec 31 2020)   (Mar 31 2019)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Lannett Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
162.89 % 3.16 % -100 %
(Sep 30 2020)  


LCINQ's III. Quarter Q/Q Revenue Comment
Lannett Company Inc achieved in the III. Quarter 2023 above company average sequential Revenue increase of 9.29%, to $ 79.46 millions, from $72.71 millions in the second quarter.
LCINQ is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 92 other companies have achieved higher Revenue quarter on quarter growth. While Lannett Inc's Revenue growth quarter on quarter, overall rank is 919.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #93
Healthcare Sector #210
Overall #919
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #93
Healthcare Sector #210
Overall #919
Revenue Q/Q Growth Statistics
High Average Low
162.89 % 3.16 % -100 %
(Sep 30 2020)  


LCINQ's III. Quarter Q/Q Revenue Comment
Lannett Company Inc achieved in the III. Quarter 2023 above company average sequential Revenue increase of 9.29%, to $ 79.46 millions, from $72.71 millions in the second quarter.
LCINQ is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 92 other companies have achieved higher Revenue quarter on quarter growth. While Lannett Inc's Revenue growth quarter on quarter, overall rank is 919.


Lannett Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 300.25 $ 299.14 $ 312.94 $ 340.58 $ 372.40
Y / Y Revenue Growth (TTM) -19.37 % -26.39 % -31.04 % -28.86 % -11.52 %
Year on Year Revenue Growth Overall Ranking # 2091 # 0 # 0 # 0 # 444
Seqeuential Revenue Change (TTM) 0.37 % -4.41 % -8.12 % -8.54 % -8.37 %
Seq. Revenue Growth (TTM) Overall Ranking # 3236 # 0 # 0 # 0 # 763


Cumulative Revenue growth Comment
Lannett Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2022. If the fiscal year would end in Mar 31 2023, Lannett Inc's annual Revenue decrease would be -19.37% year on year to $300 millions.

In the Healthcare sector 308 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2091.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 168
Healthcare Sector # 309
Overall # 2091

Revenue TTM Y/Y Growth Statistics
High Average Low
142.74 %
 15.85 %
-55.37 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 168
Sector # 457
S&P 500 # 3236
Cumulative Revenue growth Comment
Lannett Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2022. If the fiscal year would end in Mar 31 2023, Lannett Inc's annual Revenue drop would be -19.37% year on year to $300 millions.

In the Healthcare sector 308 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2091.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 168
Healthcare Sector # 309
Overall # 2091

Revenue TTM Y/Y Growth Statistics
High Average Low
142.74 %
15.85 %
-55.37 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 168
Sector # 457
S&P 500 # 3236




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LCINQ's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Iqvia Holdings Inc 2.35%$ 2.354 millions
Regen Biopharma Inc 2.25%$ 2.246 millions
Petros Pharmaceuticals inc 2.14%$ 2.141 millions
Amedisys Inc2.04%$ 2.042 millions
Davita Inc 1.96%$ 1.957 millions
Pediatrix Medical Group Inc 1.82%$ 1.821 millions
American Shared Hospital Services1.61%$ 1.609 millions
Utah Medical Products Inc1.60%$ 1.599 millions
Societal Cdmo Inc 1.57%$ 1.571 millions
Syneos Health Inc 1.54%$ 1.538 millions
Becton Dickinson And Company1.49%$ 1.495 millions
Pacira Biosciences inc 1.49%$ 1.487 millions
Ocular Therapeutix Inc 1.42%$ 1.418 millions
Lannett Company Inc1.41%$ 1.413 millions
Bausch Health Companies Inc 1.36%$ 1.356 millions
Integra Lifesciences Holdings Corp1.12%$ 1.117 millions
Procyon Corporation1.11%$ 1.108 millions
Bio techne Corp0.96%$ 0.959 millions
Embecta Corp 0.95%$ 0.947 millions
Dentsply Sirona Inc 0.93%$ 0.929 millions
Supernus Pharmaceuticals inc 0.82%$ 0.825 millions
Akumin Inc 0.71%$ 0.714 millions
Zoetis Inc 0.70%$ 0.705 millions


About Lannett Inc Revenue Growth Rates (LCINQ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lannett Co Inc (CIK 57725).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-23-009852
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lannett Co Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.